Segment and Geographic Information (Tables)

12 Months Ended

Jun. 28, 2014

Segments and Geographic Information [Abstract]

Schedule of Revenue by Geographic Location

The Company generated third-party revenues in the following geographic locations⁽¹⁾ during each of the fiscal years presented (in millions):

	2014		2013		2012
Ireland	$	146.7	$	—	$	—
U.S.	3,291.6		2,978.1		2,693.6
All other countries(2)	622.5		561.7		479.6
	$	4,060.8	$	3,539.8	$	3,173.2

⁽¹⁾ The Company attributes revenues to countries based on sales location.

⁽²⁾ Includes sales generated primarily in Israel, U.K., Mexico, Australia, and Canada.

Schedule of Property and Equipment by Geographic Location

The net book value of property and equipment at June 28, 2014 and June 29, 2013 was as follows (in millions):

	June 28, 2014		June 29, 2013
Ireland	$	2.0	$	—
U.S.	530.7		468.4
Israel	119.6		98.0
All other countries	127.6		115.0
	$	779.9	$	681.4

Schedule of Segment Reporting Information, by Segment

($ in millions)	Consumer Healthcare			Nutritionals			Rx Pharma-ceuticals			API			Specialty Sciences			Other			Unallocated expenses			Total
Fiscal 2014
Net sales	$	2,219.0		$	551.7		$	927.1		$	137.6		$	146.7		$	78.7		$	—		$	4,060.8
Operating income	$	368.6		$	40.5		$	349.8		$	46.1		$	(68.6	)	$	4.0		$	(173.4	)	$	567.0
Operating income %	16.6		%	7.3		%	37.7		%	33.5		%	(46.7		)%	5.2		%	—		%	14.0		%
Total assets	$	3,774.5		$	1,077.2		$	2,537.2		$	288.0		$	6,096.6		$	106.7		$	—		$	13,880.2
Capital expenditures	$	115.9		$	7.3		$	32.9		$	10.4		$	—		$	5.1		$	—		$	171.6
Fixed assets, net	$	475.7		$	88.6		$	104.8		$	95.7		$	2.1		$	13.0		$	—		$	779.9
Depreciation/amortization	$	63.8		$	38.5		$	86.5		$	11.4		$	154.4		$	4.3		$	—		$	358.9
Fiscal 2013
Net sales	$	2,089.0		$	508.4		$	709.5		$	159.3		—			$	73.6		$	—		$	3,539.8
Operating income	$	363.2		$	35.2		$	263.2		$	48.9		—			$	3.4		$	(34.7	)	$	679.1
Operating income %	17.4		%	6.9		%	37.1		%	30.7		%	—		%	4.6		%	—		%	19.2		%
Total assets	$	2,409.0		$	949.7		$	1,604.9		$	284.5		—			$	102.7		$	—		$	5,350.8
Capital expenditures	$	85.5		$	7.8		$	17.7		$	17.3		—			$	3.8		$	—		$	132.2
Fixed assets, net	$	404.1		$	92.8		$	80.8		$	92.7		—			$	11.1		$	—		$	681.4
Depreciation/amortization	$	53.8		$	38.3		$	54.9		$	9.1		—			$	4.0		$	—		$	160.2
Fiscal 2012
Net sales	$	1,815.8		$	501.0		$	617.4		$	165.8		—			$	73.3		$	—		$	3,173.2
Operating income	$	315.3		$	25.4		$	213.5		$	53.9		—			$	2.0		$	(40.9	)	$	569.2
Operating income %	17.4		%	5.1		%	34.6		%	32.5		%	—		%	2.7		%	—		%	17.9		%
Total assets	$	1,651.4		$	951.0		$	1,072.6		$	258.4		—			$	90.7		$	—		$	4,024.0
Capital expenditures	$	76.3		$	14.4		$	8.0		$	18.5		—			$	3.0		$	—		$	120.2
Fixed assets, net	$	328.0		$	94.5		$	67.6		$	79.6		—			$	8.7		$	—		$	578.4
Depreciation/amortization	$	41.0		$	39.0		$	42.2		$	9.3		—			$	3.8		$	—		$	135.3

Schedule of Sales by Major Product Category

The following is a summary of the Company's net sales by major product category (in millions):

	Fiscal 2014		Fiscal 2013		Fiscal 2012
Consumer Healthcare (CHC)
Cough/Cold (1)	$	510.1	$	500.6	$	447.2
Analgesics (1)	504.0		536.0		452.3
Gastrointestinal (1)	400.1		388.8		402.4
Smoking Cessation	236.8		193.2		170.6
Animal Health	178.0		123.2		—
Other CHC (1,2)	390.0		347.3		343.3
Total CHC	2,219.0		2,089.0		1,815.8
Nutritionals
Infant nutritionals	374.8		350.1		352.7
Vitamins, minerals and dietary supplements	176.9		158.3		148.3
Total Nutritionals	551.7		508.4		501.0
Generic prescription drugs	927.1		709.5		617.4
Active pharmaceutical ingredients	137.6		159.3		165.8
Specialty sciences - Tysabri®	146.7		—		—
Pharmaceutical and medical diagnostic products	78.7		73.6		73.3
Total Net Sales	$	4,060.8	$	3,539.8	$	3,173.2

⁽¹⁾ Includes sales from the Company's contract manufacturing business.

⁽²⁾ Consists primarily of feminine hygiene, diabetes care, dermatological care and other miscellaneous or otherwise uncategorized product lines and markets